Evidence map›Paper›PMID 36853804›Full record

ArticleJCI insight2023

KIBRA upregulation increases susceptibility to podocyte injury and glomerular disease progression.

Kristin Meliambro, Yanfeng Yang, Marina de Cos, Estefania Rodriguez Ballestas, Caroline Malkin, Jonathan Haydak, John R Lee, Fadi Salem, Laura H Mariani, Ronald E Gordon and 7 more

Open access · goldAbstract read
In one paragraph

Article in JCI insight, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Personalized disease recurrence modeling using iPSC-derived podocytes in patients with idiopathic nephrotic syndrome.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025
    Article
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 1 country.

Kristin MeliambroDivision of Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Yanfeng YangDivision of Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Marina de CosDivision of Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Estefania Rodriguez BallestasDivision of Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Caroline MalkinDivision of Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Jonathan HaydakDivision of Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
John R LeeDivision of Nephrology and Hypertension, Department of Medicine, Weill Cornell Medicine, New York, New York, USA.
Fadi SalemDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, Florida, USA.
Laura H MarianiDivision of Nephrology, Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Ronald E GordonDepartment of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
John M BasgenStereology and Morphometry Laboratory, Charles R. Drew University of Medicine and Science, Los Angeles, California, USA.
Huei Hsun WenDivision of Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Jia FuDivision of Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Evren U AzelogluDivision of Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
John Cijiang HeDivision of Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Jenny S WongDivision of Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Kirk N CampbellDivision of Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Icahn School of Medicine at Mount Sinai · USCharles R. Drew University of Medicine and Science · USCornell University · USJacksonville College · USUniversity of Michigan · US

Funding

Hippo-YAP in podocyte health and diseaseR01DK122807 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI Kirk N Campbell · 2019 to 2026
$4.8M
The role of dendrin in glomerular disease progressionR01DK103022 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CAMPBELL, KIRK N · 2015 to 2019
$1.9M
The Role of KIBRA Signaling in Podocyte InjuryK08DK113281 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MELIAMBRO, KRISTIN · 2018 to 2022
$896k
NIDDK NIH HHS K08 DK113281NIDDK NIH HHS R01 DK103022NIDDK NIH HHS R01 DK122807
6 · The paper itself

Abstract

Despite recent progress in the identification of mediators of podocyte injury, mechanisms underlying podocyte loss remain poorly understood, and cell-specific therapy is lacking. We previously reported that kidney and brain expressed protein (KIBRA), encoded by WWC1, promotes podocyte injury in vitro through activation of the Hippo signaling pathway. KIBRA expression is increased in the glomeruli of patients with focal segmental glomerulosclerosis, and KIBRA depletion in vivo is protective against acute podocyte injury. Here, we tested the consequences of transgenic podocyte-specific WWC1 expression in immortalized human podocytes and in mice, and we explored the association between glomerular WWC1 expression and glomerular disease progression. We found that KIBRA overexpression in immortalized human podocytes promoted cytoplasmic localization of Yes-associated protein (YAP), induced actin cytoskeletal reorganization, and altered focal adhesion expression and morphology. WWC1-transgenic (KIBRA-overexpressing) mice were more susceptible to acute and chronic glomerular injury, with evidence of YAP inhibition in vivo. Of clinical relevance, glomerular WWC1 expression negatively correlated with renal survival among patients with primary glomerular diseases. These findings highlight the importance of KIBRA/YAP signaling to the regulation of podocyte structural integrity and identify KIBRA-mediated injury as a potential target for podocyte-specific therapy in glomerular disease.

Indexed as

Kidney DiseasesPodocytesAnimalsDisease ProgressionHumansIntracellular Signaling Peptides and ProteinsKidney GlomerulusMiceSignal TransductionUp-RegulationIntracellular Signaling Peptides and ProteinsWWC1 protein, humanCell BiologyCell migration/adhesionChronic kidney diseaseNephrology

Identifiers

PMID36853804
PMCPMC10132156
OpenAlexW4322616985

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.